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Mesenchymal stem cells (MSCs) are widely used in cell therapy and tissue engineering
thanks to their self-renewal, their multipotency, and their immunomodulatory properties
that make them an attractive tool for regenerative medicine. A large part of MSCs
positive effects is due to their secretion products which participate in creating a
favorable microenvironment and closely relate these cells to other cell types. Extracellular
vesicles (EVs) belong to cellular secretions. They are produced by cells continuously
or after stimulation (e.g., calcium flux, cellular stress) and act in tissue homeostasis
and intercellular communication. The understanding of the role of EVs is growing,
more particularly their impact on cell migration, differentiation, or immunomodulation.
EVs derived from MSCs show these interesting properties that may be considered in
therapeutics, although they can have adverse effects by facilitating cancer propagation.
Moreover, MSC behavior may also be influenced (proliferation, differentiation) by EVs
derived from other donor cells. The aim of this mini review is to summarize the two-way
communication between MSCs and other cell types, and how they can affect each other
with their microenvironment through EVs. On the one hand, the manuscript presents the
influence of MSC-derived EVs on diverse recipient cells and on the other hand, the effects
of EVs derived from various donor cells on MSCs. The discrepancies between cancer
cells and MSCs communication according to the sources of MSCs but also the tumor
origins are also mentioned.
Keywords: mesenchymal stem cells (MSCs), extracellular vesicles (EVs), recipient/donor cells, intercellular
communication, microenvironment
INTRODUCTION
At physiological level, the cells composing a tissue, an organ, or even an entire organism are
constantly trading information either by physical contact or by long distance communication. This
phenomenon allows their maintenance but can also lead to variations in the cellular behavior. The
study of these interactions has permitted to develop new therapeutic strategies such as cell therapies.
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Thanks to their self-renewal, their multipotency, and their
immunomodulatory properties, mesenchymal stem cells (MSCs)
are an attractive tool for regenerative medicine. For example,
MSCs are used in clinical trials to treat pathologies such as
graft vs. host disease (GvHD) (Le Blanc et al., 2008; Zhou et al.,
2010; Introna et al., 2014), although concerns remain regarding
efficacy, safety, and feasibility of such treatments (Si et al., 2011;
Mendicino et al., 2014). The most common sources of MSCs
are from adult origin like bone marrow or adipose tissue, but
their collects request an invasive procedure. Perinatal sources
like Wharton’s jelly from umbilical cord offer more accessibility
and larger quantities of MSCs with higher proliferation rate and
greater immunomodulatory properties (El Omar et al., 2014).
Numerous studies have shown the regenerative potential of
MSCs to counteract organ failures (Xing et al., 2014; Desando
et al., 2016; Sattayaprasert et al., 2016). It has also been
demonstrated that injecting MSC conditioned medium and not
the cells themselves can induce the same effects. This is due
to the composition of MSC secretions, which are of two types,
soluble factors [e.g., soluble tumor necrosis factor receptor 1,
transforming growth factor (TGF-β) 1; (Melief et al., 2013; Ke
et al., 2016)] or extracellular vesicles (EVs). EVs are involved
in tissue reparation, immunomodulation, and proliferation. A
miscellaneous EV population can be found in biological fluids.
Three kinds of EVs are mostly described by the scientific
FIGURE 1 | Intercellular communication between MSCs and other cell types through EVs. Upper panels: MSCs as recipient cells. Lower panels: MSCs as
donor cells. Left Panels: MSCs exchanging with differentiated cells. Right Panels: Cross-talk between MSCs and cancer cells. CTGF, connective tissue growth
factor; EV, extracellular vesicle; FGF, fibroblast growth factor; HSP, heat shock protein; IL, interleukin; mRNA, messenger RNA; miRNA or miR, microRNA; MSC,
mesenchymal stem cell; PDGF, platelet-derived growth factor; PD-L1, programmed death-ligand 1; SMA, smooth muscle actin; TGF, transforming growth factor;
VEGF, vascular endothelial growth factor.
community according to their size and biogenesis (Höög and
Lötvall, 2015; Yáñez-Mó et al., 2015; Kowal et al., 2016). The
biggest vesicles are secreted after cell apoptosis and are large EVs
from 1 to 5µm called apoptotic bodies (Atkin-Smith et al., 2015).
EVs from 0.1 to 1 µm are termed microparticles, ectosomes,
or microvesicles. They are generally produced by cells during
stress or metabolic changes and result from the budding of the
plasma membrane (Ratajczak et al., 2006). Endosome-derived
EVs named exosomes are small EVs—with a size varying from
30 to 150 nm depending on the literature—which are secreted
continuously whatever cellular state (stress or physiological
conditions) (Valadi et al., 2007; György et al., 2011; Vlassov et al.,
2012; Crescitelli et al., 2013). The size similarity between EVs can
impair their identification if size is used as the only parameter for
characterization. Lately, the difficulties to purify a homogeneous
EV population and to select appropriate EV markers to classify
them have been discussed and remain. All vesicle populations will
be referred as EVs in this mini review and the attention will be
highlighted on their biological effects.
MSCs are commonly known as donor cells by providing EVs
to other cells types, nevertheless their part as recipient cells is
less described (Figure 1). A recent report shows that human
bone marrow (BM)-MSCs can be both donor and recipient
cells. Osteogenically induced BM-MSCs are donors of EVs which
are able to guide osteogenic differentiation. The stimulation
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of recipient BM-MSCs by these EVs induces expression of
bone morphogenic protein (BMP)-2, osterix, osteopontin (OPN),
osteocalcin (OCN), and alkaline phosphatase (ALP). Thus, the
recipient BM-MSCs may be employed for therapeutic use to
improve bone regeneration (Martins et al., 2016). Each cell
produces its own secretions which allow the formation of its own
microenvironment affecting surrounding cells including MSCs.
In this mini review, we focus on the effects of EV exchange
between MSCs and other cell types in both ways.
MSCs AS DONOR CELLS
MSC-EVs and Tissue Regeneration
MSC microenvironment acts differently depending on the target
cells (Figure 1). MSC-EVs can produce modifications in gene
expression and mediate cell maturation or differentiation. For
example, osteoblasts undergoing stimulation with EVs originated
from BM-MSCs show clear calcium deposits in vitro in the same
way as osteogenic medium stimulation. This is supported by
ALP, OCN, OPN, and runt-related transcription factor (RUNX)2
gene overexpression. These in vitro results were confirmed in
vivo by using hydrogels supplemented with EVs to improve bone
regeneration through the expression of micro RNA miR-196a.
MSC-EVs induce angiogenesis stimulation of human
umbilical vein endothelial cells by enhancing tube formation
in MatrigelTM-coated wells. This observation has been made
with fresh or frozen EVs, showing their preservation potential
under −80◦C (Teng et al., 2015). Montemurro et al. showed that
EVs derived from cord blood MSCs carry transcripts related
to angiogenic and proliferative function such as connective
tissue growth factor (CTGF), fibroblast growth factor (FGF),
interleukin (IL)-6 but also TGF-ß1, and vascular endothelial
growth factor (VEGF) (Montemurro et al., 2016). Transcripts
were not the only ones to participate in the pro-angiogenic
properties of MSC-EVs. Pro-angiogenic properties beneficial
for myocardial tissue repair were highlighted after MSC pre-
conditioning by serum starvation plus low oxygen settings in
order to mimic ischemic conditions after myocardial infarction.
Modification of culture conditions leads to modulation of
protein targeting toward MSC-EVs. Specific protein content
during stimulation has an effect in angiogenesis and especially
by nuclear factor (NF)-κB signaling pathway (Anderson et al.,
2016). Intramyocardial injection of MSCs or MSC-EVs also
reduces myocardial ischemia in rats 48 h after infarction.
Compared to the control, MSCs or MSC-EVs showed similar
effects with reduction of the infarct size 28 days after post-
operation. Injection of EVs derived from MSCs also improved
cardiac function and promoted the number of blood vessels
in myocardium infarcted region with a higher increase than
MSC injection (Bian et al., 2014). In skeletal muscle, MSC-
EVs are able to improve tissue repair. The specific content
in growth factors (VEGF, fibroblast growth factor, platelet-
derived growth factor-BB), cytokines (IL-1β, IL-6, IL-8), and
especially in non-coding RNA may act to maintain a healthy
and functional tissue. Three important myogenic micro RNAs
(miRNAs: miR-1, -133, and -206) that have been involved in
muscle regeneration after injection in rat model appear inside
MSC-EVs. Although miR-494 is not specific for muscle repair,
it was also found in high concentration inside MSC-EVs.
This miRNA participates in myogenesis, migration activity,
and protects against ischemia/reperfusion injury in cardiac
muscle (Nakamura et al., 2015; Hofer and Tuan, 2016). The
potential of MSC-EVs to treat cardiovascular injuries is widely
studied. During ischemia, tissue oxygenation becomes almost
null, but during this time, MSCs secrete large amounts of
EVs containing a high concentration of miR-22 compared to
normoxic conditions. Interactions between EVs containing
miR-22 and cardiomyocytes allows a reduction of infarcted zone
volume and apoptosis in the ischemic myocardium by the down
regulation of methyl CpG binding protein 2 (Mecp2) (Feng et al.,
2014). Another study highlights the beneficial effect of MSC-EVs
on cardiomyocytes survival, this effect being higher when MSCs
overexpress transcription factor GATA-4 (Yu et al., 2015). Wang
et al. have pointed miR-223 in MSC-EVs as a primordial effector
in cardioprotective properties. During polymicrobial sepsis,
miR-223 contained inside EVs contributes to the regulation of
two proteins, semaphorin-3A (Sema3A) and signal transducer
and activator of transcription 3 (Stat3), which are involved in
apoptosis. The absence of miR-223 inside MSC-EVs has an
impact on cardiac cells and may have deleterious effects. On
the contrary, his presence will allow a better defense against
sepsis (Wang et al., 2015). Furthermore, MSC-EV regenerative
potential has been demonstrated in neurogenesis (Xin et al.,
2013), liver fibrosis (Li et al., 2013), and cutaneous wound
healing (Zhang et al., 2015).
MSC-EVs and Immunomodulation
MSC-EVs take place in immunomodulation to lower the immune
system activation through the induction of anti-inflammatory
cytokines and regulatory T cells (Treg) (Figure 1) (Del Fattore
et al., 2015), but also by regulating macrophages polarization
(Ti et al., 2015) and neutrophils mobilization (Zhu et al., 2014).
More generally, MSC-EVs have been shown to balance expansion
of myeloid progenitors (Goloviznina et al., 2016). MSC-EVs
can activate monocytes by Toll-like receptor (TLR) signaling
pathway. In contrast with activation by lipopolysaccharides
(LPS), the surface receptor involved is unknown but will
cause the same signaling cascade via myeloid differentiation
primary response gene 88 (MYD88) and NF-κB (Zhang et al.,
2014). Another notable difference is observed in cytokine
production. Thus, when monocytes are stimulated by MSC-
EVs, they differentiate into macrophages which secrete IL-
10, leading to Treg expansion. During this study, test of
skin allograft rejection by mice treated with MSC-EVs showed
similar results with another experiment using cyclosporine A,
an immunosuppressor (Zhang et al., 2014). MSC-EVs can
induce the decrease of B lymphocyte and natural killer (NK)
cell proliferation. Unlike MSCs, EV immunomodulation is
not mediated by indoleamine-pyrrole 2,3-dioxygenase (IDO)
pathway but by a molecule on their surface: programmed death-
ligand (PD-L)1 (Di Trapani et al., 2016). To be activated, MSCs
need to be stimulated by pro-inflammatory cytokines to trigger
their immunosuppressive answer. Generally, an increase of IDO
activity is a marker of activation when MSCs and T cells
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are in contact, but during contact between MSC-EVs and T
cells, IDO concentration remains stable without modifying the
immunological potential. In addition to PD-L1, an endogenous
leptin found on EV surface—galectin-1—is also involved in
the immunomodulatory response (Del Fattore et al., 2015).
Effects of 5′-ectonucleotidase (CD73) has been studied as well
because this enzyme found on MSCs and MSC-EVs actively
produces adenosine, amolecule known to be immunosuppressive
(Kerkelä et al., 2016). Moreover, inflammatory priming induces
the increase of miR-155 and -146 level inside MSC-EVs. These
specific miRNAs intervene in the regulation of inflammatory
reactions (Di Trapani et al., 2016). Clinical applications are
also possible to reduce inflammation in some pathologies such
as therapy refractory GvHD. Shortly after MSC-EV therapy,
cutaneous, and mucosal GvHD showed a very promising
response, allowing to reduce four times the administrated steroid
doses. Such EV-based treatment have beneficial effects for the
patient without side effects (Kordelas et al., 2014).
MSC-EVs in Cross-Talk with Cancer Cells
Despite the numerous studies about pro-angiogenic effects of
MSC-EVs, these vesicles may have a reverse effect on cancer cells.
A study on mouse breast cancer cell line (4T1) headed by Lee
et al. showed that miR-16 level in EVs derived from mouse BM-
MSCs contributes to decrease the secretion of VEGF by cells.
These modifications lead to a suppression of angiogenesis in
vitro and thus a reduction in tumor spread (Lee et al., 2013).
In the case of cancers therapy with MSC-EVs, there are a lot
of divergences between studies because of the source of MSCs,
the tumor origin, but also the timing of stimulation with EVs
(Figure 1). Depending on the papers, MSC-EVs can promote
tumor progression (Roccaro et al., 2013; Shi et al., 2016), decrease
it (Bruno et al., 2013), or have no effect (Hendijani et al.,
2015). In all cases, the content in cytokines and miRNAs seems
to be the key factor. The effect of nucleic acids contained in
EVs in the cross-talk between tumor cells and MSCs has been
well-described by Lopatina et al. (2016). They came to the
conclusion that these cells exchange either oncogenic and anti-
tumoral RNAs. For example, EVs secreted by multiple myeloma
BM-MSCs display a lower tumor suppressive miR-15a content
(Roccaro et al., 2013), associated with more cytokines regulating
cell adhesion and migration as well as oncogenic proteins.
When stimulated with MSC-EVs, cells from nasopharyngeal
carcinoma (CNE2) undergo toward a mesenchymal transition,
with a decrease of epithelial markers like epithelial cadherin (Shi
et al., 2016). MSC-EVs used on different cancer cell lines can also
stimulate metalloproteinase (MMP)-2 expression, thus helping
tumor migration (Yang et al., 2015). These vesicles have also
the ability to transfer CD73 on tumor cells, giving them the
ability to metabolize AMP into adenosine, which reduces NK and
T cell activation. MSC-EVs can also confer drug resistance to
gastric cancer cells by stimulating multidrug resistance protein
expression and reducing chemo-induced apoptosis (Ji et al.,
2015). However, liver cancer cell lines like HepG2 stimulated
with MSC-EVs have difficulties in the cell cycle progression and
are subject to apoptosis (Bruno et al., 2013). In vivo growth of
glioma xenografts is also reduced by miR-146 which is present
in MSC-EVs (Katakowski et al., 2013). The chemosensitivity
of hepatocellular carcinoma cells was also raised by miR-122
contained in adipose-tissue MSC-EVs. Some cell lines remain
unaffected byMSC-EVs, neither in a pro- nor an anti-tumor way.
For example, when the lung cancer cell line A549 is exposed
to umbilical cord MSCs conditioned medium, it does not lose
or gain proliferation rate, even if MSCs are stimulated with
interferon γ. The association of conditioned medium with the
therapeutic agent doxorubicin does not modify its native effect
(Lou et al., 2015). Even if the direct use of MSC-EVs in cancer
therapies is still not fully understood and should be carefully
controlled, it appears that they could be an interesting vector to
address therapeutic cargos to tumors (Chen et al., 2011; Johnsen
et al., 2014; Yang et al., 2015).
MSCs AS RECIPIENT CELLS
EVs from Differentiated Cells
EVs derived from differentiated cells are able to modulate MSC
phenotype (Figure 1). An in vitro study has highlighted the
potential of EVs derived from neuronal cells to mediate MSC
neuronal induction. Indeed, miR-125b—which is known to act
in neuronal differentiation—is expressed byMSCs after 1 week of
stimulation by these EVs (Takeda and Xu, 2015). When derived
from endothelial cells, EVs can influence MSC proliferation,
migration, and secretion of soluble factors such as matrix MMP-
1, MMP-3, chemokine ligand 2 (CCL-2), and IL-6 (Lozito and
Tuan, 2014). In the case of renal tubular morphogenesis and
kidney structure, cells known as mesenchymal-epithelial cells
are required. The origin of these cells can be explained by the
migration and transition of MSCs from bone marrow induced
by EVs derived from human renal proximal tubular epithelial
cells. The presence of the miR-200 family (miR-200a, -200b,
and -200c) has been highlighted in these EVs. Their uptake
by BM-MSCs induces a MSC phenotype modification with
a mesenchymal to epithelial transition, characterized by the
acquisition of polarized epithelial cell properties by BM-MSCs.
This is a physiological process involved in kidney formation
(Chiabotto et al., 2016). Immune cells such as monocytes
communicate also with MSCs via EVs. LPS activated monocytes
secrete a lot of soluble factors as well as EVs. The conditioned
medium of these cells has the property to modulate MSC
phenotype by upregulating osteogenic gene expression (Omar
et al., 2011).RUNX2, BMP-2, andOCN expression were evaluated
after 72 h of MSC stimulation by conditioned medium or EVs
derived from activated monocytes compared to control. During
EVs stimulation, RUNX2 and BMP-2 were significantly increased
compared to control in the same way as conditioned medium
but OCN was only over expressed with EVs. This indicates
that EVs derived from activated monocyte promote osteogenic
differentiation in MSCs (Ekström et al., 2013). In a rat model
of calvarial bone defect, it has been shown that EVs obtained
from induced pluripotent stem cell-derived MSCs associated
to a tricalcium phosphate scaffold are able to stimulate bone
regeneration by recruiting BM-MSCs at the defect site. The
rat’s BM-MSCs are activated through the phosphatidylinositol 3
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kinase (PI3K)/Akt pathway leading to osteogenic differentiation
(Zhang et al., 2016).
EVs from Cancer Cells
Genetic modifications of MSCs are also possible via EV transfer
from cancer cells (Figure 1). When EVs are originated from
healthy cells, their effects seem beneficial. However, when EVs
come from cancer cells, their influence onMSCs may be harmful.
Lindoso et al. have demonstrated that EVs derived from renal
cancer stem cells can induce epigenetic changes in recipient
cells. MSCs are attracted to the tumor region and change their
phenotype, becoming pro-tumorigenic. This correlates with the
overexpression of genes involved in cell migration: chemokine
receptor type (CXCR)4 and CXCR7; matrix remodeling: collagen
type IV alpha 3 chain (COL4A3); as well as angiogenesis and
tumor growth: IL-8, OPN, and myeloperoxidase. EVs secreted
by cancer stem cells allow a better chemoattraction of MSCs,
which promote tumor development and spread (Lindoso et al.,
2015). There are also differences in the evolution of MSC
phenotype which is reliant on the origin of EVs. Thus,
MSCs can differentiate into myofibroblasts under action of
EVs from prostate cancer. The myofibroblastic marker alpha-
smooth muscle actin α-SMA) is expressed by more than 50%
of MSCs exposed to prostate cancer derived EVs vs. only 5%
of cells under TGF-ß1 stimulation, which is known to induce
α-SMA expression. There is also a correlation between the
quantity of EVs and α-SMA acquisition (Chowdhury et al.,
2015). This differentiation has also been demonstrated with
EVs from breast cancer cells or chronic lymphocytic leukemia
(Cho et al., 2011; Paggetti et al., 2015). Another example of
MSC phenotype modification has been highlighted by Li et al.
during a study about lung tumor EVs. In vitro, EVs from the
lung cancer line A549 stimulate the production and secretion
of inflammatory cytokines in MSCs. Three cytokines: IL-6, IL-8,
and monocyte chemoattractant protein (MCP)-1 were released
by MSCs when they are triggered by A549 cell-derived EVs.
The priming of MSCs by lung cancer cell-derived EVs would
occur through the activation of TLR2/NF-κB signaling by the
interaction of EVs surface heat shock protein 70 (HSP70) with
cells (Li et al., 2016). In a different experiment, EVs from KMBC
(human cholangiocarcinoma cells) enhance modifications of
MSCs toward a fibroblastic phenotype. Such transformation is
not the only change:MSCs brought into contact with KMBC-EVs
subsequently secrete IL-6 which causes an increase in cancer cells
proliferation (Haga et al., 2015). Chronic myelogenous leukemia
(CML) uses the same pathway to spread. CML-EVs interact
with BM-MSCs and this stimulation initiates IL-8 production
by MSCs which permits CML cells proliferation (Corrado et al.,
2014). The cross-talk between MSCs and cancer cells leads to
a specific sequence. First, cancer cells interact with MSCs via
their EVs to modulate them and in response, the modified MSCs
participate in cancer progression trough their own EVs (Corrado
et al., 2014; Haga et al., 2015).
CONCLUSION
Cellular communication by EVs relies on the nature of donor
cells and recipient cells (Figure 1). Research on MSC-EVs is
prolific and shows their potential in regenerative medicine,
whereas there is less literature about EVs originated from healthy
differentiated cells. For these last, the difficulties may originate
from a low proliferation and a poor EV production in vitro. In
the case of cancers, the mechanisms of the cross-talk between the
tumor and MSCs are yet not fully unraveled, but some works on
EVs as therapeutic cargo show promising results.
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